Navigation Links
ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule
Date:6/24/2009

i-centre, randomized, placebo controlled, double-masked trials which will evaluate 125micro g of microplasmin versus placebo in the intravitreal treatment of patients with focal vitreomacular adhesion. The trials will enrol a total of approximately 320 patients each across approximately 40 centres in the United States (TG-MV-006) and 40 centres in Europe and North America (TG-MV-007). The safety review was the final of two safety reviews, and had been scheduled to take place after 50% of patients had been enrolled in one of the studies.

The primary endpoint of both trials is the non-surgical resolution of focal vitreomacular adhesion within one month. Additional measures of efficacy and safety will also be assessed at various intervals over six months in both studies. It is estimated that these two studies will be completed by the end of 2010.

Dr. Steve Pakola, Chief Medical Officer of ThromboGenics, commenting on the announcement said, "We are very pleased that the Phase III program for microplasmin is progressing well and that enrolment is on track. We remain confident that microplasmin could potentially make a significant difference to the treatment of back of the eye disease and we very much look forward to reporting the results from these trials."

About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of innovative biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications and as a potential therapy for stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
8. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... DUBLIN , Apr. 24, 2015 /PRNewswire/ ... ) has announced the addition of the ... Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station) & ... Institute) - Global Forecast to 2020" ... global laboratory accessories market is expected to ...
(Date:4/24/2015)... , April 24, 2015  Lannett Company, Inc. (NYSE: ... and increased its five-year revolving credit facility to $120 ... accordion feature that will allow the company to increase ... $30.0 million, subject to securing additional commitments from existing ... the credit facility remains December 18, 2018.   ...
(Date:4/23/2015)... 24, 2015  AbbVie (NYSE: ABBV ) has ... has accepted its New Drug Application (NDA) and granted ... antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin ... with chronic genotype 4 (GT4) hepatitis C virus (HCV) ... interferon-free therapy being evaluated by the FDA for patients ...
Breaking Medicine Technology:Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 2Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 3Lannett Expands Revolving Credit Facility To $120 Million 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7
... Nov. 22, 2011 Cadence Pharmaceuticals, Inc. (Nasdaq: ... previously announced public offering of 21,800,000 shares of its ... full exercise of an over-allotment option previously granted to ... per share.  The net proceeds from the offering, after ...
... Nov. 22, 2011  Medical Science Liaisons are the ... in the marketplace. Biopharmaceutical and medical device companies ... services to a diverse set of customers that ... opinion leaders, payer and government thought leaders, and ...
Cached Medicine Technology:Cadence Pharmaceuticals Announces Completion of Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option by Underwriters 2Delivering Exceptional Medical Science Liaison Services to Key Stakeholders in the Marketplace 2
(Date:4/25/2015)... The Hon. Ellen Tauscher, Independent Chair ... following statement following the deadly earthquake in Nepal: , ... in the deaths of more than 1,000 people. ... Nepal, Bangladesh, India and other parts of South Asia. ... the people of Nepal and the families of the ...
(Date:4/25/2015)... April 25, 2015 By definition, a CIO’s ... for the enterprise relying on their judgement and expertise to ... But according to an article published in National Mortgage ... actually be doing a disservice to their responsibilities by focusing ... and t’s are crossed when it comes to company policy ...
(Date:4/25/2015)... April 25, 2015 Parker and Sons projects ... cooling, has spiked in Arizona alongside the growing economy. As ... forty employees for April to help account for the rising ... employees in April is something we are enthusiastic about. It ... Paul Kelly, president at Parker and Sons. , Indeed, Parker ...
(Date:4/25/2015)... For thirteen years, the Twin Cities DI Day ... in the nation! This year, on May 5th, 2015, Secura ... take DI Day on the road by supporting the first ... RHU, DIA, CLTC, Chief Executive Officer at Secura Consultants and ... change by stating, "The first Twin Cities DI Day was ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 As the ... and the unique sacrifices of these young men and ... Service members, Veterans and their Families” presents a special ... is designed to gain a better understanding of the ... and wellness. For those – civilian and military – ...
Breaking Medicine News(10 mins):Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 2Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 4Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 5Health News:Parker and Sons Plans to Expand in 2015 2Health News:Secura Consultants Takes DI Day On The Road 2Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2
... , WASHINGTON, Sept. 9 As Obama prepares to ... League challenged the nation,s Catholic bishops to be prepared to shut ... this action to compromising with the intrinsic evils currently contained in ... http://www.newscom.com/cgi-bin/prnh/20081105/DC44231LOGO ) , , ...
... , BOSTON, Sept. 9 A ... a result of laboratory use and confinement. Developmental Context ... published in the September issue, Vol. 45 (5), of the ... . , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090909/DC72238 ) ...
... ... Child Safety , ... (PRWEB) September 9, 2009 -- September sees more than 500,000 children head back to school ... do parents keep their kids safe when they are in someone else’s care? , , ...
... CITY, Calif., Sept. 9 Abaxis, Inc. (Nasdaq: ABAX ... today that Clint Severson, chairman and chief executive officer, will present ... Thursday, September 17, 2009 at 10:00 a.m. ET. The conference will ... City. , , About Abaxis ...
... Fla., Sept. 9 Workforce Prescriptions ("WRX") announced on Tuesday the ... national quality award, funded by a private endowment, developed to honor ... foster efficient labor practices without resorting to workforce reductions or dramatic ... easy thing to make the paradigm shift in understanding required to ...
... The following is a heartfelt opinion piece about the ... Carise for the Phoenix House blog. A ... adjunct clinical professor at the University of Pennsylvania and director of ... perspective of a leading substance abuse treatment and research professional - ...
Cached Medicine News:Health News:A.L.L.: Bishops Must Choose Between Christ-Centered Care and Obamacare 2Health News:Chimpanzees Suffer Psychologically Like Humans 2Health News:Chimpanzees Suffer Psychologically Like Humans 3Health News:Keeping Kids Safe Through Education 2Health News:WRX Launches National Labor Efficiency Quality Award 2Health News:WRX Launches National Labor Efficiency Quality Award 3Health News:DJ AM: Why He Went Too Far - Phoenix House Thought Piece for National Recovery Month by Dr. Deni Carise 2Health News:DJ AM: Why He Went Too Far - Phoenix House Thought Piece for National Recovery Month by Dr. Deni Carise 3Health News:DJ AM: Why He Went Too Far - Phoenix House Thought Piece for National Recovery Month by Dr. Deni Carise 4
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Each handle is designed to fit a specific trephine size....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: